Salicylic Acid Lotion
Name: Salicylic Acid Lotion
- Salicylic Acid Lotion 5 mg
- Salicylic Acid Lotion drug
- Salicylic Acid Lotion action
- Salicylic Acid Lotion adverse effects
Clinical pharmacology
Salicylic acid has been shown to produce desquamation of the horny layer of skin while not effecting qualitative or quantitative changes in the structure of the viable epidermis. The mechanism of action has been attributed to a dissolution of intercellular cement substance. In a study of the percutaneous absorption of salicylic acid in a 6% salicylic acid gel in four patients with extensive active psoriasis, Taylor and Halprin showed that the peak serum salicylate levels never exceeded 5 mg/100 ml even though more than 60% of the applied salicylic acid was absorbed. Systemic toxic reactions are usually associated with much higher serum levels (30 to 40 mg/100 ml). Peak serum levels occurred within five hours of the topical application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extracellular space, patients with a contracted extracellular space due to dehydration or diuretics have higher salicylate levels than those with a normal extracellular space. (See PRECAUTIONS.)
The major metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%) and free salicylic acid (6%). The urinary metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more salicylate glucuronides and less salicyluric and salicylic acid. Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space. Fifty to eighty percent of salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the action of these drugs. By similar competitive mechanisms other drugs can influence the serum levels of salicylate. (See PRECAUTIONS.)
I. Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur: | |
DRUG | DESCRIPTION OF INTERACTION |
Sulfonylureas | Hypoglycemia potentiated. |
Methotrexate | Decreases tubular reabsorption; clinical toxicity from methotrexate can result. |
Oral Anticoagulants | Increased bleeding. |
II. Drugs changing salicylate levels by altering renal tubular reabsorption: | |
DRUG | DESCRIPTION OF INTERACTION |
Corticosteroids | Decreases plasma salicylate level; tapering doses of steroids may promote salicylism. |
Acidifying Agents | Increases plasma salicylate levels. |
Alkanizing Agents | Decreased plasma salicylate levels. |
III. Drugs with complicated interactions with salicylates: | |
DRUG | DESCRIPTION OF INTERACTION |
Heparin | Salicylate decreases platelet adhesiveness and interferes with hemostasis in heparin-treated patients. |
Pyrazinamide | Inhibits pyrazinamide-induced hyperuricemia. |
Uricosuric Agents | Effect of probenemide, sulfinpyrazone and phenylbutazone inhibited. |
The following alterations of laboratory tests have been reported during salicylate therapy: | |
LABORATORY TESTS | EFFECT OF SALICYLATES |
Thyroid Function | Decreased PBI; increased t3 uptake. |
Urinary Sugar | False negative with glucose oxidase; false positive with Clinitest with high-dose salicylate therapy (2-5g q.d.). |
5-Hydroxyindole acetic acid | False negative with fluorometric test. |
Acetone ketone bodies | False positive FeCI3 in Gerhardt reaction; red color persists with boiling. |
17-OH corticosteroids | False reduced values with >4.8g q.d. salicylate. |
Vanilmandelic acid | False reduced values. |
Uric Acid | May increase or decrease depending on dose. |
Prothrombin | Decreased levels; slightly increased prothrombin time. |
Contraindications
Salicylic Acid 6% should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients.
Salicylic Acid 6% should not be used in children under 2 years of age.
Dosage and administration
The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application. The medication is washed off in the morning and if excessive drying and/or irritation is observed, a bland cream or lotion may be applied. Once clearing is apparent, the occasional use of Salicylic Acid 6% will usually maintain the remission. In those areas where occlusion is difficult or impossible, application may be made more frequently; hydration by wet packs or baths prior to application apparently enhances the effect. (See WARNINGS.) Unless hands are being treated, hands should be rinsed thoroughly after application. Excessive repeated application of Salicylic Acid 6% will not necessarily increase its therapeutic benefit, but could result in increased local intolerance and systemic adverse effects such as salicylism.
How supplied
Salicylic Acid 6% Cream is available in 16 oz (454 g) bottles, NDC 42937-711-16
Salicylic Acid 6% Lotion is available in 16 fl. oz (473 mL) bottles, NDC 42937-712-16 Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F), however such exposure should be minimized. Protect from freezing.